Medicortex International (MEDFIN) Q1 2025 earnings summary

Executive summary

• Q1 2025 marked by strategic focus on structural deals and investment opportunities, with ongoing evaluation of new business prospects after ending reverse acquisition talks with Brasseriegruppen.

• Market conditions in Sweden remain challenging but offer opportunities for companies with active acquisition agendas.

Financial highlights

• Group net revenue for Q1 2025 was 1,345 TKR, down 39% year-over-year; parent company net revenue was 79 TKR, up 509% due to invoiced services to subsidiaries.

• Group operating result improved to -864 TKR from -2,359 TKR; parent company operating result improved to -546 TKR from -1,168 TKR.

• Group net result attributable to parent shareholders was -1,130 TKR (vs. -3,375 TKR); parent company net result was -712 TKR (vs. -2,374 TKR).

• Cash flow from operating activities improved to -839 TKR (group) and -518 TKR (parent), reflecting cost reductions.

Outlook and guidance

• NOSIUM continues to pursue strategic investments and structural deals, with ongoing dialogues with unlisted companies aiming for public listing.

• Management sees favorable market conditions for executing a major transaction in 2025.